Article Details

Roche gets EMA panel nod for conditional approval of Lunsumio for blood cancer subtype in EU

Retrieved on: 2022-04-22 14:24:52

Tags for this article:

Click the tags to see associated articles and topics

Roche gets EMA panel nod for conditional approval of Lunsumio for blood cancer subtype in EU. View article details on hiswai:

Excerpt

A committee of the European Medicines Agency (EMA) recommended the conditional approval of Roche' (RHHBY) (RHHBF) Lunsumio to treat adult patients ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up